News
Anal Cancer
Bladder Cancer
Bone Cancer
Brain Cancer
Breast Cancer
Cancer of Unknown Primary
Cervical Cancer
Colon Cancer
Esophageal Cancer
Gastric Cancer
GIST
Head & Neck Cancer
Hodgkins Lymphoma
Leukemia
Acute Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Liver Cancer
Lung Cancer
Melanoma
Mesothelioma
Multiple Myeloma
Myelodysplastic Syndrome
MPN-PV-ET-MF
Neuroblastoma
Neuroendocrine Tumors
Non Hodgkins Lymphoma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Renal Cancer
Rectal Cancer
Sarcoma
Skin Care
Skin Cancer
Testicular Cancer
Thyroid Cancer
Triple Negative Breast Cancer
Uterine Cancer
About Us
Advertising
News
Newly Diagnosed
Treatment & Care
Survivorship
Join the Community
Newsletter
Search
Ovarian Cancer Treatment
November 27, 2023
Raludotatug Deruxtecan (R-Dxd) in Ovarian Cancer
Charles H. Weaver, MD
April 8, 2023
Botensilimab + Balstilimab Produces High Response Rates in Advanced Ovarian Cancer
Charles H. Weaver, MD
November 25, 2022
Understanding DNA Damage Response or DDR and Cancer Treatment
Charles H. Weaver, MD
August 15, 2022
Intraperitoneal Chemotherapy Treatment of Ovarian Cancer
Charles H. Weaver, MD
February 6, 2022
Mekinist for Low Grade Ovarian Cancer
Charles H. Weaver, MD
June 23, 2021
Elahere (mirvetuximab soravtansine)
Charles H. Weaver, MD
March 4, 2021
Update on PARP Inhibitors & Other Precision Cancer Medicines for Ovarian Cancer
Charles H. Weaver, MD
January 7, 2021
Overview of Ovarian Cancer
Charles H. Weaver, MD
November 16, 2020
Precision Cancer Medicines for Ovarian Cancer
Charles H. Weaver, MD
September 23, 2020
Lynparza Delays Progression & Significantly Prolongs Survival in Ovarian Cancer
Charles H. Weaver, MD
September 2, 2020
Berzosertib – A Novel ATR Inhibitor in Development
Charles H. Weaver, MD
August 22, 2020
Treatment & Management of Ovarian Cancer
Charles H. Weaver, MD
1
2
Next Page
Loading Comments...
Write a Comment...
Email (Required)
Name (Required)
Website
